目的 基于网络药理学探讨夏荔芪胶囊治疗良性前列腺增生的作用机制。方法 通过查询中药系统药理学数据库与分析平台（TCMSP）、BATMAN-TCM、Swiss数据库获取夏荔芪胶囊的活性成分及作用靶点，通过Genecards、OMIM、中医药综合数据库（TCMID）获取治疗良性前列腺增生的作用靶点，利用R软件获取药物和疾病共有靶点；利用STRING平台对共有靶点构建蛋白质-蛋白质相互作用（protein-protein interaction，PPI）网络；利用R软件对共有靶点进行基因本体（gene ontology，GO）、京都基因与基因组百科全书（Kyoto encyclopedia of genes and genomes，KEGG）富集分析；利用Cytoscape软件构建药物-成分-靶点-通路网络。结果 共得到夏荔芪胶囊活性成分77个、靶点127个，良性前列腺增生作用靶点929个；映射后得到夏荔芪胶囊作用于良性前列腺增生的潜在靶点65个，与调节类固醇反应、氧化应激反应和凋亡信号通路等相关，相关度较高的靶点为α1型肾上腺素能受体（α1 A-adrenergic receptor blocker，Alpha1）、5α还原酶（5α-reductases，S5AR）、雄激素受体（androgen receptor，AR）、血管内皮生长因子A （vascular endothelial growth factor A，VEGFA）、雌激素受体1（estrogen receptor 1，ESR1），涉及磷脂酰肌醇-3-激酶（phosphoinositide 3-kinase，PI3K）-蛋白激酶B （protein kinase B，Akt）、p53和丝裂原活化蛋白激酶（mitogen-activated protein kinases，MAPK）信号通路。结论 夏荔芪胶囊可能通过抑制前列腺细胞增殖、舒张尿道平滑肌、促进前列腺细胞凋亡，从而治疗良性前列腺增生。

Objective To explore the mechanism of Xialiqi Capsule (夏荔芪胶囊) on treating benign prostatic hyperplasia based on network pharmacology. Methods The active components and targets of Xialiqi Capsule were searched by TCMSP, BATMAN-TCM, and Swiss databases. The targets of benign prostatic hyperplasia were searched by GeneCards, OMIM, and TCMID databases. The common targets of Xialiqi Capsule and benign prostatic hyperplasia were screened by R software. Protein-protein interaction (PPI) network for common targets was constructed by String platform. Gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) enrichment analyses were carried out by R software. The drug-component-target-pathway network was established by Cytoscape. Results A total of 77 active components, 127 targets, and 929 disease targets were obtained. After mapping, 65 potential targets of Xialiqi Capsules for benign prostatic hyperplasia were obtained, which related to the regulation of steroid response, oxidative stress response and apoptosis signaling pathway. The targets of high correlation were α1 A-adrenergic receptor blocker (Alpha1), 5α-reductases (S5AR), androgen receptor (AR), vascular endothelial growth factor A (VEGFA), and estrogen receptor 1 (ESR1), involving phosphoinositide 3-kinase-protein kinase B (PI3K-Akt), p53, and mitogen-activated protein kinases (MAPK) signaling pathways. Conclusion Xialiqi Capsule could treat benign prostatic hyperplasia through inhibiting prostate growth, relaxing of urethral smooth muscle, and promoting of prostate cell apoptosis.

R285.5

国家自然科学基金培育项目（XY20-13）；中国中医科学院西苑医院苗圃课题项目（2019XYMP-23）